Physician profile
Harry S Ojeas
NPI 1528051042
$14,536.73
in general payments reported to CMS, 2019-2025
35 companies · $2,662 in 2025
The $2,662 reported for 2025 was more than what 85% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,321 · 2020: $1,167 · 2021: $2,144 · 2022: $2,683 · 2023: $2,887 · 2024: $674 · 2025: $2,662.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,181 · Education: $41.29.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,181.38 |
| Education | $41.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,498.63 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $2,041.40 | 2019-2025 | Xifaxan, Trulance, Relistor |
| Takeda Pharmaceuticals U.S.A., INC. | $1,795.74 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Gilead Sciences, INC. | $1,264.03 | 2019-2025 | |
| Celgene Corporation | $773.55 | 2021-2023 | Zeposia |
| Redhill Biopharma INC. | $705.98 | 2021-2025 | Talicia, Aemcolo, Movantik |
| Ironwood Pharmaceuticals, INC | $676.57 | 2019-2025 | Linzess |
| Braintree Laboratories, INC. | $560.82 | 2019-2025 | Sutab, Suflave |
| Janssen Biotech, INC. | $522.08 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Madrigal Pharmaceuticals | $495.94 | 2024-2025 | Rezdiffra, Resmetirom |
| Ardelyx, INC. | $376.10 | 2022-2025 | Ibsrela |
| Intercept Pharmaceuticals, INC. | $269.55 | 2019-2023 | Ocaliva |
| Evoke Pharma, INC. | $246.40 | 2022-2025 | Gimoti |
| Celltrion USA INC. | $232.57 | 2023-2025 | Vegzelma, Yuflyma, Zymfentra |
| Romark Laboratories, Lc | $185.97 | 2019-2020 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $155.92 | 2019-2025 | Rebyota |
| Nestle Healthcare Nutrition INC. | $89.14 | 2022 | |
| Cumberland Pharmaceuticals, INC. | $87.75 | 2019 | |
| Shire North American Group INC | $75.22 | 2019 | |
| Allergan, INC. | $72.11 | 2019 | |
| Shionogi INC | $61.03 | 2019-2020 | |
| Pfizer INC. | $51.82 | 2025 | |
| Genzyme Corporation | $48.82 | 2023 | |
| Pharmacosmos Therapeutics INC. | $47.26 | 2021 | |
| Aimmune Therapeutics, INC. | $41.41 | 2024-2025 | Zenpep |
| Qol Medical, LLC | $41.17 | 2019 | |
| Ambu INC. | $26.37 | 2021 | |
| Alnylam Pharmaceuticals INC. | $23.62 | 2021 | |
| Novo Nordisk INC | $20.89 | 2025 | Wegovy |
| Vivus LLC | $20.32 | 2023 | Pancreaze |
| Merck Sharp & Dohme LLC | $16.78 | 2020 | |
| Cook Medical LLC | $11.77 | 2019 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$11,834.32 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Harry Ojeas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.